About this trial
This study explores the electrophysiological mechanisms underlying motor and non-motor fluctuations (NMF) in Parkinson's disease (PD), focusing on cortical and subthalamic dynamics during acute dopaminergic stimulation.
PD is characterized by both motor symptoms and disabling non-motor symptoms-including neuropsychiatric fluctuations that remain poorly understood. While local field potentials (LFP) recorded from the subthalamic nucleus (STN) via deep brain stimulation (DBS) have revealed beta-band abnormalities linked to motor dysfunction, little is known about the oscillatory signatures of NMF. Preliminary data from our group suggested that gamma-band EEG activity in frontotemporal regions may correlate with neuropsychiatric fluctuations.
This Swiss, two-center, prospective observational study aims to investigate resting-state electroencephalogram (EEG) and STN-LFP correlates of motor and non-motor symptoms during a modified levodopa challenge in 30 PD patients with STN-DBS. Using high-density EEG and chronically implanted Medtronic Percept™ DBS devices, electrophysiological data will be collected across five clinical states (combinations of ON/OFF levodopa and DBS). Clinical symptoms will be assessed alongside electrophysiological activity to identify frequency-specific cortical-STN biomarkers. Machine learning models (e.g., LASSO regression) will be used to predict motor and non-motor states from EEG and LFP data, enabling the identification of dynamic oscillatory markers. This could inform future adaptive DBS strategies.
The study leverages advanced methods in neurophysiology, imaging, and machine learning to deepen our understanding of PD fluctuations. It also proposes the first detailed electrophysiological mapping of NMF, which could improve patient stratification and neuromodulation therapies. Anatomical validation of DBS lead placement will be performed using standard neuroimaging toolkits.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of Parkinson's disease (PD) based on United Kingdom Parkinson's Disease Society Brain Bank Criteria.
Patients candidate for STN-DBS in the PD phase called fluctuations stage.
To be on dopaminergic therapy.
Patients who have undergone STN-DBS implantation within 4 to 8 weeks before electrophysiological acquisition.
Disqualifiers
Patients with an age greater than 80 years,
Dementia (defined by a MOCA score ≤24),
Active psychosis or depression with suicidal ideation,
Any clinically meaningful non-stable physical diseases,
Trial population
STN-DBS Parkinson's disease patients
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Correlation over-time of STN intracranial LFP activity and EEG resting-state oscillatory activity
Correlation over-time of STN intracranial LFP activity and EEG resting-state oscillatory activity (spectral, temporal and spatial features as well as cortical-subcortical and cortico-cortical coherence) with the temporal dynamics of motor and non-motor clinical scores
Secondary outcomes
Temporal dynamics of motor and non-motor clinical scores
Temporal dynamics of motor and non-motor clinical scores
Correlation of EEG and STN LFP markers of motor and non-motor response to levodopa
Correlation of EEG and STN LFP markers of motor and non-motor response to levodopa with the extensive ON-OFF-DRT motor, cognitive and emotional clinical scores response to levodopa.
Dynamic modulations of the oscillatory coupling between the STN and the cortex
Dynamic modulations of the oscillatory coupling between the STN and the cortex in the canonical frequency bands and their correlation with the temporal dynamics of motor and non-motor clinical scores during the acute phase following levodopa administration
Difference in resting-state EEG power in frequency bands linked to motor and non-motor symptoms improvement, between different DBS conditions
Difference in resting-state EEG power in frequency bands linked to motor and non-motor symptoms improvement, between ON-DBS and OFF-DBS in the ON-drug and OFF-drug conditions, and correlation with motor and non-motor symptoms improvement secondary to DBS
Sponsors and contacts
Click on the lead sponsor to view all of their trials.